VIVUS (VVUS) Resumes Trading +17%
Share of VIVUS Inc. (Nasdaq: VVUS) resume trading up 17% after the FDA approved obesity drug Qsymia.
You May Also Be Interested In
- UPDATE: Impax Laboratories (IPXL) Issued Form 483 Following FDA Inspection of Taiwan Facility
- El Pollo Loco (LOCO) Continues Surge Following 1-Day Pause
- Emergent Biosolutions (EBS) Issued CRL from FDA on IXINITY
Create E-mail Alert Related CategoriesFDA, Momentum Movers, Trader Talk, Trading Halts
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!